Faslodex
Breast, Malignant Neoplasms, PI3K Gene Mutation + 4 more
Treatment
8 FDA approvals
1 Active Study for Faslodex
Treatment for
Breast
What is Faslodex
Fulvestrant
The Generic name of this drug
Treatment Summary
Fulvestrant is a medication used to treat metastatic breast cancer in postmenopausal women whose cancer has progressed even after taking anti-estrogen therapy. It works by blocking the estrogen receptors in the body and reducing their levels. It is usually prescribed as a single drug, but can also be used in combination with alpelisib for certain types of breast cancer.
Faslodex
is the brand name
Faslodex Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Faslodex
Fulvestrant
2010
29
Approved as Treatment by the FDA
Fulvestrant, commonly known as Faslodex, is approved by the FDA for 8 uses which include Progression, Disease and Advanced or Metastatic Breast Cancer .
Progression, Disease
Used to treat Progression, Disease in combination with Abemaciclib
Advanced or Metastatic Breast Cancer
Used to treat Advanced or Metastatic Breast Cancer in combination with Abemaciclib
PI3K Gene Mutation
Used to treat PI3K Gene Mutation in combination with Alpelisib
Disease
Used to treat disease progression after endocrine based therapy in combination with Alpelisib
PIK3CA Gene Mutation
Used to treat PIK3CA Gene Mutation in combination with Alpelisib
Malignant Neoplasms
Used to treat Advanced or Metastatic Breast Cancer in combination with Abemaciclib
Disease Progression
Used to treat Progression, Disease in combination with Abemaciclib
prior endocrine therapy
Used to treat prior endocrine therapy in combination with Abemaciclib
Effectiveness
How Faslodex Affects Patients
Fulvestrant is a drug that is injected directly into the muscle and works by blocking the effects of estrogen in the body. It does not have any estrogen-like effects itself.
How Faslodex works in the body
Fulvestrant works by stopping estrogen from attaching to cancer cells. It does this by attaching to the cells instead of estrogen, blocking the hormone from binding. It also breaks down the cells' estrogen receptors so they can no longer bind to the hormone. This prevents the growth of both tamoxifen-resistant and estrogen-sensitive breast cancer cells.
When to interrupt dosage
The measure of Faslodex relies upon the recognized affliction, including Progression, Disease, Breast and PIK3CA Gene Mutation. The quantity of dosage differs, as specified by the technique of delivery (e.g. Solution or Injection) featured in the table beneath.
Condition
Dosage
Administration
Breast
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
PIK3CA Gene Mutation
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
Malignant Neoplasms
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
PI3K Gene Mutation
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
Disease Progression
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
Disease
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
prior endocrine therapy
, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg
Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection
Warnings
There are 2 known major drug interactions with Faslodex.
Common Faslodex Drug Interactions
Drug Name
Risk Level
Description
Ospemifene
Major
The risk or severity of adverse effects can be increased when Fulvestrant is combined with Ospemifene.
Fluoroestradiol F-18
Moderate
Fulvestrant may decrease effectiveness of Fluoroestradiol F-18 as a diagnostic agent.
Faslodex Toxicity & Overdose Risk
There has not been a case of overdosage in humans.
Faslodex Novel Uses: Which Conditions Have a Clinical Trial Featuring Faslodex?
There are 20 active investigations examining the potential of Faslodex to inhibit Progression of Disease, Breast Malignancies and Neoplasms.
Condition
Clinical Trials
Trial Phases
Breast
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Disease
0 Actively Recruiting
PIK3CA Gene Mutation
0 Actively Recruiting
Disease Progression
0 Actively Recruiting
PI3K Gene Mutation
1 Actively Recruiting
Phase 1
prior endocrine therapy
0 Actively Recruiting
Faslodex Reviews: What are patients saying about Faslodex?
5
Patient Review
4/4/2014
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
5
Patient Review
10/27/2016
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
5
Patient Review
6/5/2015
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
5
Patient Review
6/3/2014
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
4.7
Patient Review
7/16/2014
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
4.7
Patient Review
1/19/2016
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
4.7
Patient Review
12/1/2021
Faslodex for Hormone Receptor Positive Postmenopausal Advanced Breast Cancer
4.3
Patient Review
2/16/2015
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
3.7
Patient Review
10/16/2019
Faslodex for malignant tumor or cancer
3.3
Patient Review
5/31/2021
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
2.7
Patient Review
12/30/2019
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
1.7
Patient Review
6/24/2015
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
1.7
Patient Review
10/6/2018
Faslodex for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
Patient Q&A Section about faslodex
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Faslodex chemotherapy?
"Faslodex is a type of hormone therapy, not a chemotherapy drug or an aromatase inhibitor. Chemotherapy works by killing the cells in your body that multiply quickly."
Answered by AI
What is the drug Faslodex used for?
"Faslodex is a drug used to treat advanced-stage breast cancer that is positive for hormone receptors and negative for HER2. It works by downregulating estrogen receptors. It can be used alone or in combination with other targeted therapies."
Answered by AI
What are side effects of Faslodex?
"The side effects of the medication include pain at the injection site, headache, pain in the muscles, joints, or bones, back pain, pain in the hands, feet, arms, or legs, hot flashes, nausea and vomiting, and loss of appetite."
Answered by AI
Is Faslodex chemotherapy or immunotherapy?
"Faslodex is primarily used as a hormonal therapy to limit the amount of estrogen in the body, which may help to treat breast cancer. It is sometimes used in combination with other medications."
Answered by AI